Related Experiment Video

Updated: Jun 25, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and

Corey J Langer

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |February 20, 2009
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Jun 25, 2026

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial.

    The Lancet. Respiratory medicine·2026

    Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC.

    Clinical lung cancer·2026

    EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung Cancer.

    JCO precision oncology·2026

    Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461].

    The journal of liquid biopsy·2026

    Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study.

    Frontiers in oncology·2026

    The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing.

    The journal of liquid biopsy·2026

    Development and Validation of a Blood Test Informed Risk Prediction Model for Lung Cancer-The Copenhagen Lung Cancer Risk Model (CPH-Lung).

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505).

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Prognostic Impact of Telomere Maintenance Mechanisms in Neuroblastoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us